Trials / Terminated
TerminatedNCT04330079
Effects of dapaglifloziN Therapy on Myocardial Perfusion Reserve in Prediabetic Patients With Stable coronarY Artery Disease
Effects of dapaglifloziN Therapy on Myocardial Perfusion Reserve in Prediabetic Patients With Stable coronarY Artery Disease (ENTRY Trial)
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- CHEOL WHAN LEE, M.D., Ph.D · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the effects of dapagliflozin therapy on myocardial perfusion reserve (MPR) using dynamic SPECT examination in prediabetic patients with stable CAD. Dapagliflozin therapy versus lifestyle modification improves myocardial perfusion reserve in prediabetic patients with stable CAD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dapagliflozin 10mg | Dapagliflozin 10mg once daily for 6 months. |
| OTHER | Lifestyle modification | lifestyle modification (diet and exercise) for 6 months |
Timeline
- Start date
- 2020-05-21
- Primary completion
- 2021-04-08
- Completion
- 2021-04-08
- First posted
- 2020-04-01
- Last updated
- 2022-09-23
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04330079. Inclusion in this directory is not an endorsement.